Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates.
Clin Pediatr (Phila)
; 33(6): 349-52, 1994 Jun.
Article
em En
| MEDLINE
| ID: mdl-8200169
ABSTRACT
The purpose of this study was to determine the role of intravenous immunoglobulin (IVIG) administration in preterm neonates with S. typhimurium infection. A randomized trial of 47 preterm neonates with intestinal or extraintestinal S. typhimurium infection was performed. Neonates were randomly divided into two groups 22 neonates were only given cefoperazone (group 1); 25 neonates were given cefoperazone plus IVIG (group 2). IVIG was given at a dose of 500 mg/kg on days 1, 2, 3, and 8 after entry into the study. Following treatment, bacteremia, complications, mortality rate, recovery time, and duration of antimicrobial therapy were evaluated in two groups. Bacteremia was found in 31.4% in group 1 and 8% in group 2 (P < .05); complications developed in 81.8% in group 1 and 16% in group 2 (P < 0.01); mortality was 40.9% in group 1 and 12% in group 2 (P < .05). Recovery took 15 days in group 1 and 8 days in group 2 (P < .01). The duration of antimicrobial therapy was 20 days in group 1 and 14 days in group 2 (P < .01). We conclude that IVIG treatment in combination with antibiotics in preterm neonates with S. typhimurium infection reduces the complications, mortality rate, and duration of therapy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por Salmonella
/
Salmonella typhimurium
/
Imunoglobulinas Intravenosas
/
Doenças do Prematuro
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Male
/
Newborn
Idioma:
En
Revista:
Clin Pediatr (Phila)
Ano de publicação:
1994
Tipo de documento:
Article
País de afiliação:
Turquia